BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

Benzinga · 4d ago
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.